Given that the inflammation plays a detrimental role in colon carcinogenesis1, our data therefore indicate that, during the inflammatory phase or the early stage of tumorigenesis, increasing DHX9 expression by ATRA treatment ameliorates the intestinal inflammatory damage and blocks tumor progression in a time-dependent manner. This evidence concerns the gene DHX9 and neoplasm.